Literature DB >> 29404242

Rhabdomyosarcoma of the Head and Neck: A Multimodal Approach.

Dana L Casey1, Suzanne L Wolden1.   

Abstract

Head and neck rhabdomyosarcoma (HNRMS) is a uniquely challenging site to treat given the young patient age and critical anatomy of the head and neck region. We review the characteristics, management, and future directions in the treatment of HNRMS. Most patients who present with HNRMS have unresectable disease due to functional and/or cosmetic constraints. However, surgical resection and brachytherapy serve a critical role in select patients. The treatment paradigm for the majority of patients with HNRMS consists of definitive chemotherapy and radiation therapy. As the incidence of late toxicities increases with improved survival, modern efforts must focus on ways to decrease long-term morbidity. We recommend a multimodal approach emphasizing the preservation of form and function for the treatment of HNRMS.

Entities:  

Keywords:  brachytherapy; head and neck neoplasms; pediatric rhabdomyosarcoma; radiotherapy

Year:  2018        PMID: 29404242      PMCID: PMC5796820          DOI: 10.1055/s-0037-1617450

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  40 in total

1.  Rhabdomyosarcoma: many similarities, a few philosophical differences.

Authors:  Sarah S Donaldson; James R Anderson
Journal:  J Clin Oncol       Date:  2005-02-22       Impact factor: 44.544

2.  Adverse events of local treatment in long-term head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment.

Authors:  Reineke A Schoot; Olga Slater; Cécile M Ronckers; Aeilko H Zwinderman; Alfons J M Balm; Benjamin Hartley; Michiel W van den Brekel; Sanjeev Gupta; Peerooz Saeed; Eva Gajdosova; Bradley R Pieters; Mark N Gaze; Henry C Mandeville; Raquel Davila Fajardo; Yen Ch'ing Chang; Jennifer E Gains; Simon D Strackee; David Dunaway; Christopher Abela; Carol Mason; Ludi E Smeele; Julia C Chisholm; Gill A Levitt; Leontien C M Kremer; Martha A Grootenhuis; Heleen Maurice-Stam; Charles A Stiller; Peter Hammond; Huib N Caron; Johannes H M Merks
Journal:  Eur J Cancer       Date:  2015-05-18       Impact factor: 9.162

3.  Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups.

Authors:  J H M Merks; G L De Salvo; C Bergeron; G Bisogno; A De Paoli; A Ferrari; A Rey; O Oberlin; M C G Stevens; A Kelsey; J Michalski; D S Hawkins; J R Anderson
Journal:  Ann Oncol       Date:  2014-01       Impact factor: 32.976

4.  Consistent chromosomal translocation in alveolar rhabdomyosarcoma.

Authors:  C Turc-Carel; S Lizard-Nacol; E Justrabo; M Favrot; T Philip; E Tabone
Journal:  Cancer Genet Cytogenet       Date:  1986-01-15

5.  Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.

Authors:  John Breneman; Jane Meza; Sarah S Donaldson; R Beverly Raney; Suzanne Wolden; Jeff Michalski; Fran Laurie; David A Rodeberg; William Meyer; David Walterhouse; Douglas S Hawkins
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-19       Impact factor: 7.038

6.  Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: A descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and - III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group.

Authors:  R B Raney; L Asmar; R Vassilopoulou-Sellin; M J Klein; S S Donaldson; J Green; R Heyn; M Wharam; A S Glicksman; E A Gehan; J Anderson; H M Maurer
Journal:  Med Pediatr Oncol       Date:  1999-10

7.  Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  R Beverly Raney; David O Walterhouse; Jane L Meza; Richard J Andrassy; John C Breneman; William M Crist; Harold M Maurer; William H Meyer; David M Parham; James R Anderson
Journal:  J Clin Oncol       Date:  2011-02-28       Impact factor: 44.544

8.  Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma.

Authors:  Matthew M Ladra; Jackie D Szymonifka; Anita Mahajan; Alison M Friedmann; Beow Yong Yeap; Claire P Goebel; Shannon M MacDonald; David R Grosshans; Carlos Rodriguez-Galindo; Karen J Marcus; Nancy J Tarbell; Torunn I Yock
Journal:  J Clin Oncol       Date:  2014-10-20       Impact factor: 44.544

9.  The Intergroup Rhabdomyosarcoma Study-II.

Authors:  H M Maurer; E A Gehan; M Beltangady; W Crist; P S Dickman; S S Donaldson; C Fryer; D Hammond; D M Hays; J Herrmann
Journal:  Cancer       Date:  1993-03-01       Impact factor: 6.860

Review 10.  Biology and therapy of pediatric rhabdomyosarcoma.

Authors:  A S Pappo; D N Shapiro; W M Crist; H M Maurer
Journal:  J Clin Oncol       Date:  1995-08       Impact factor: 44.544

View more
  5 in total

1.  Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide.

Authors:  Dana L Casey; Leonard H Wexler; Suzanne L Wolden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-30       Impact factor: 7.038

2.  Therapeutic outcome and prognostic factors in sinonasal rhabdomyosarcoma: a single-institution case series.

Authors:  Wanpeng Li; Hanyu Lu; Dehui Wang
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-23       Impact factor: 4.553

3.  Non-orbital Sclerosing Rhabdomyosarcoma Presented With Optic Neuropathy.

Authors:  Maizatul Nadia Hassan; Wan Hazabbah Wan Hitam; Nurul Ain Masnon; Chandran Nadarajan
Journal:  Cureus       Date:  2022-01-09

Review 4.  [Treatment and management of orbital tumors].

Authors:  Michael Zimbelmann; Birte Neppert; Roya Piria; Neele Babst; Katharina A Ponto; Salvatore Grisanti; Ludwig M Heindl; Vinodh Kakkassery
Journal:  Ophthalmologe       Date:  2021-08-18       Impact factor: 1.059

5.  Evaluation of clinical efficacy of Chemotherapy for Rhabdomyosarcoma in children.

Authors:  Zhaohui Ning; Xiping Liu; Guang Qin; Lei Wei; Xia Li; Jingjing Shen
Journal:  Pak J Med Sci       Date:  2020 Jul-Aug       Impact factor: 1.088

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.